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AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan
Anti-retroviral therapy (ART) is crucial for controlling human immunodeficiency virus
type-1 (HIV-1) infection. Recently, progress in identifying and characterizing highly potent
broadly neutralizing antibodies has provided valuable templates for HIV-1 therapy and
vaccine design. Nevertheless, HIV-1, like many RNA viruses, exhibits genetically diverse
populations known as quasispecies. Evolution of quasispecies can occur rapidly in
response to selective pressures, such as that exerted by ART and the immune system.
Hence, rapid viral evolution leading to drug resistance and/or immune evasion is a
significant barrier to the development of effective HIV-1 treatments and vaccines. Here,
we describe our recent investigations into evolutionary pressure exerted by anti-retroviral
drugs and monoclonal neutralizing antibodies (NAbs) on HIV-1 envelope sequences. We
also discuss sensitivities of HIV-1 escape mutants to maraviroc, a CCR5 inhibitor, and
HIV-1 sensitized to NAbs by small-molecule CD4-mimetic compounds. These studies
help to develop an understanding of viral evolution and escape from both anti-retroviral
drugs and the immune system, and also provide fundamental insights into the combined
use of NAbs and entry inhibitors. These findings of the adaptation and evolution of HIV
in response to drug and immune pressure will inform the development of more effective
antiviral therapeutic strategies.
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INTRODUCTION
Human immunodeficiency virus type-1 (HIV-1) exhibits extremely high genetic diversity
(Rambaut et al., 2004) indicating that rapidly changing genetic variation can confer on the
virus the capacity to escape the immune system and anti-retroviral therapy (ART). The HIV-1
components presenting the highest degree of sequence diversity are the surface-expressed viral
envelope glycoproteins (Env), which are prime targets for both entry inhibitors and neutralizing
antibodies (NAbs) (Goulder and Watkins, 2008).
The function of Env is to facilitate the entry of HIV-1 into the target cell, a process mediated
by recognition of the CD4 receptor and coreceptor (usually CCR5 or CXCR4) on the cellular
membrane (Dalgleish et al., 1984; Klatzmann et al., 1984; Choe et al., 1996; Deng et al., 1996;
Doranz et al., 1996; Dragic et al., 1996; Feng et al., 1996). Env is composed of the surface
glycoprotein, gp120, and the transmembrane glycoprotein, gp41, which associate as a non-covalent
complex to form a single subunit of a trimeric viral envelope spike (Wyatt and Sodroski, 1998).
Gp120 is responsible for interactions with CD4 and the coreceptor, whereas gp41 anchors the Env
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machinery at the viral membrane and induces membrane fusion
during viral entry (Freed and Martin, 1995; Bazan et al., 1998).
Many entry inhibitors have been developed to block the
interaction of Env with the CD4 receptor, the coreceptor, or
the fusion reaction. Currently, two entry inhibitors have been
approved for clinical use, the fusion inhibitor, enfuvirtide (T-20)
(Robertson, 2003), and the CCR5 inhibitor, maraviroc (MVC)
(Dorr et al., 2005; Gulick et al., 2008). As with any anti-retroviral
drug, HIV can develop resistance to T-20 and MVC. The
major mechanism of resistance to T-20 is caused by mutations
within the binding site on the HR1 region of gp41 (Greenberg
and Cammack, 2004) (Figure 1C). On the other hand, clinical
resistance to MVC involves different genetic alterations in env
giving rise to highly divergent Env phenotypes (Roche et al.,
2013). Potential molecular mechanisms of resistance to MVC
include tropism switching to CXCR4-using (X4) viruses (Westby
et al., 2006; Raymond et al., 2015), increased kinetics of the
entry step (Reeves et al., 2002; Putcharoen et al., 2012), increased
affinity for CD4 and/or CCR5 (Agrawal-Gamse et al., 2009;
Pugach et al., 2009; Pfaff et al., 2010; Ratcliff et al., 2013), and
utilization of MVC-bound CCR5 for entry (Pugach et al., 2007;
Westby et al., 2007; Tilton et al., 2010; Roche et al., 2011).
In recent years, progress in identifying and characterizing
highly potent broadly NAbs (bNAbs), has provided valuable
templates for HIV-1 therapy and vaccine design (Kwong and
Mascola, 2012; Kwong et al., 2013; Burton and Mascola, 2015;
Burton and Hangartner, 2016). However, attempts to elicit such
highly potent bNAbs by immunization have not been successful,
due in part to the high genetic diversity of Env and the complex
escape mechanisms employed by Env (Seaman et al., 2010).
Moreover, the replication capacity of HIV-1 is largely related
to the efficiency of viral entry (Arts and Quinones-Mateu, 2003;
Rangel et al., 2003). In this respect, evolutionary patterns of
Env are important, and selective pressures exerted by NAbs
and anti-retroviral drugs can contribute to its evolution. Thus,
elucidation of these patterns would inform the development of
more effective antiviral therapeutic strategies.
Recently, we investigated dynamic features of selective
pressure on Env by assessing NAb sensitivities of HIV-1
escape mutants from MVC, and small-molecule CD4-mimetic
compounds (CD4mc) that sensitize HIV-1 to NAbs. Thus, we
summarize these recent advances and discuss the application of
these findings to the development of more effective combinations
of NAbs and anti-retroviral drugs.
FUNDAMENTALS OF HIV ENTRY
Entry of HIV-1 into a target cell involves interactions between
Env and the two-receptor mechanism involving CD4 and the
coreceptor. This interaction activates conformational changes in
Env that lead to the membrane fusion reaction (Sattentau and
Moore, 1995) (Figure 1B).
Gp120 is composed of five conserved regions (C1 to C5) that
are interspersed with five variable regions (V1 to V5) (Starcich
et al., 1986) (Figure 1C). The CD4 binding site (CD4bs) and
especially the Phe 43 cavity, where Phe 43 of CD4 contacts gp120,
are highly conserved among the different subtypes (Kwong et al.,
1998). Following the binding of CD4 and gp120, the gp120
core undergoes conformational changes, moving from a rigid
(unliganded) to a flexible state, allowing a subsequent interaction
with the coreceptor (Myszka et al., 2000) (Figure 1B). Binding
of gp120 to the coreceptor triggers further conformational
changes in Env that fuse the viral membrane with the target
cell membrane (Chan and Kim, 1998). Current models suggest
the V3 tip interacts with the coreceptor second extracellular
loop (ECL2), whereas the gp120 bridging sheet and the V3 stem
interact with the coreceptor N terminus (Brelot et al., 1999;
Farzan et al., 1999; Cormier and Dragic, 2002; Huang et al., 2005)
(Figure 1A).
PRESSURE OF NAbs ON THE
EVOLUTION OF Env
Recently, bNAbs have been isolated from HIV-1-infected
individuals. Most major target specificities of these bNAbs have
been mapped to various sites on Env, and include the V2 N160
glycan (V2 apex), the V3 N332 glycan (high-mannose patch),
the CD4bs, the gp120/41 interface region, the fusion peptide
(FP), and the membrane proximal external region (MPER) of
gp41 (Burton and Mascola, 2015; Burton and Hangartner, 2016;
Kong et al., 2016; van Gils et al., 2016). In addition, CD4
binding exposes highly conserved cryptic epitopes recognized by
V3-directed or CD4-induced (CD4i) NAbs, which recognize the
coreceptor binding site (Kwong and Mascola, 2012) (Figure 1B).
The V3-directed NAb, KD-247, is a humanized NAb with
potent neutralizing activity. The epitope recognized by KD-247
was mapped to the IGPGR sequence of the V3-tip, which covers
about half of subtype B. A phase-1b clinical study indicates
that KD-247 reduces viral load in patients with chronic HIV-1
infection (Matsushita et al., 2015). However, HIV-1 can escape
from the adaptive immune responses, and can become resistant
to all anti-retroviral drugs. Therefore, in our previous in vitro
study, we induced resistant variants against KD-247 using the
JR-FL strain (Yoshimura et al., 2006). Resistance against KD-247
was associated with G314E substitution in the epitope on the
V3-tip. Unexpectedly, the KD-247-resistant variant exhibited
higher sensitivity to CCR5 inhibitors (TAK-779, aplaviroc and
SCH-C) compared with the parental virus. Furthermore, our
data showed strong synergistic interactions between KD-247 and
CCR5 inhibitors (Yoshimura et al., 2006).
In addition to our studies, recent investigations of passive NAb
therapy in HIV-infected individuals demonstrated that particular
bNAbs could reduce levels of plasma viremia and suppress
neutralization-sensitive viruses (Caskey et al., 2015; Lynch et al.,
2015; Matsushita et al., 2015; Bar et al., 2016). However, a single
use of NAbs could not suppress HIV completely and poses
the danger of inducing escape variants in vivo. These findings
suggest that combination strategies containing NAbs are needed
to maintain virus suppression and prevent appearance of NAb-
escape variants. Therefore, in the near future, combinations of
NAbs and CCR5 inhibitors are likely to be efficient weapons
against HIV-1.
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FIGURE 1 | Human immunodeficiency virus type-1 (HIV-1) Env. (A) Entry of HIV-1 into a host cell involves interactions between the Env and the two-receptor
mechanism of CD4 and the coreceptor. (B) Tertiary schematic view of HIV-1 Env. Following the binding of CD4 and gp120, gp120 undergoes conformational
changes, moving from a rigid (unliganded) to a flexible state, allowing a subsequent interaction with the coreceptors. bNAbs have been identified that target the V2
apex, the V3 high-mannose patch, the CD4bs, the gp120/41 interface, the FP, and the MPER of gp41. In the CD4-bound state, a larger area is uncovered and
potentially available for recognition by NAbs, such as V3-directed or CD4i, which recognize the conserved coreceptor-binding site. (C) Linear schematic view of
HIV-1 Env. Gp120 is composed of five conserved regions (C1 to C5) that are interspersed with five variable regions (V1 to V5).
EFFECT OF MVC-RESISTANCE
MUTATIONS ON SENSITIVITY TO NAbs
The main mechanism of resistance to MVC appears to be related
to changes in the V3 region, which enables the virus to utilize
MVC-bound CCR5 coreceptors. The resistance is characterized
by reductions in the maximal percent inhibition (MPI) value
rather than shifts in the IC50 value (Pugach et al., 2007; Roche
et al., 2011).
Pugach et al. noted that resistant variants against two
CCR5 inhibitors (vicriviroc and AD101) were more sensitive
to several types of NAbs compared with the parental virus
(Pugach et al., 2008; Berro et al., 2009). Subsequently, we have
reported the resistance induction of the primary KP-5P virus
(subtype B, R5) against MVC in vitro (Yoshimura et al., 2014).
Resistance to MVC was associated with V200I, T297I, K305R,
and M434I substitutions near the CCR5 binding site. This
MVC-resistant variant also exhibited extremely high sensitivity
to three NAbs: b12 (CD4bs), 4E9C (CD4i), and KD-247. These
results indicated that the MVC-resistance mutations might
improve the accessibility of epitopes for the NAbs and, therefore,
be incompatible with resistance to the NAbs (Yoshimura et al.,
2014). More recently, Kuwata et al. (2015) showed that resistant
variants against a CCR5 inhibitor, cenicriviroc, also became
sensitive to three NAbs: VRC01 (CD4bs), 4E9C, and 0.5γ (V3).
Another mechanism of resistance to MVC appears to be by
a change in coreceptor tropism from CCR5 to CXCR4, or by
the selection of minority variants of X4 or dual/mixed viruses
(Westby et al., 2006). Indeed, Raymond et al. (2015) has reported
that half of MVC-treated patients who experienced virological
failure harbored X4 viruses at failure. Remarkably, previous
studies have shown that early X4 variants are more sensitive
to NAbs compared with their coexisting R5 variants (Ganesh
et al., 2004; Lusso et al., 2005; Margolis and Shattock, 2006;
Bunnik et al., 2007). In addition, increased CCR5 affinity is also
a potential resistance mechanism, but we have shown that low-
CCR5 affinity-adapted variants also became sensitive to CD4bs
and CD4i NAbs (Yoshimura et al., 2014). Thus, several studies
have demonstrated diverse resistance mechanisms against MVC,
but all these resistance pathways might drive viral evolution into a
corner, escape from which would require high sensitivity to NAbs.
Moreover, these observations indicate that MVC and NAbs might
limit the emergence of mutants that are resistant to each other,
supporting the clinical use of combination therapy (Figure 2A).
However, it is not clear whether patients’ plasma IgG
under MVC treatment can induce mutations in Env to
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FIGURE 2 | Schematic view of the relationship between NAb resistance and CCR5 inhibitor resistance (A), and the function of CD4mc (B).
(A) Selection pressures on HIV-1 Env by NAbs and/or CCR5 inhibitors might turn the tide in the fight against HIV-1. The relationship indicates that NAbs and CCR5
inhibitors may restrict the emergence of variants that are resistant to each other. (B) CD4mc is a bifunctional entry inhibitor. The use of bifunctional entry inhibitors
that display direct blockade of viral entry and exposure of epitopes to NAbs, should be effective in passive NAb immunization.
enhance neutralizing activity. We are currently investigating
the relationship between NAb responses and MVC treatment
using patients’ plasma IgGs before and after MVC-containing
combination ART (cART). Moreover, we think treatment with
particular entry inhibitors and/or CD4mc can induce bNAbs
in vivo; however, we await results for this prediction. Thus, we
will perform experiments in animal models to induce or enhance
NAbs using novel entry inhibitors and/or CD4mc treatment.
ANTI-RETROVIRAL PRESSURE ON THE
SELECTION OF Env
Evolution of HIV-1 helps it to evade NAbs (Moore et al., 2012;
Liao et al., 2013; Bouvin-Pley et al., 2014). cART, however, results
in a reduction in the virus population size, which creates a
genetic bottleneck. In vivo studies indicate that the bottleneck
affects not only drug-target regions (e.g., reverse transcriptase),
but also other regions of the viral genome, including the Env
region (Zhang et al., 1994; Sheehy et al., 1996; Delwart et al.,
1998; Nijhuis et al., 1998; Ibanez et al., 2000; Kitrinos et al.,
2005; Charpentier et al., 2006; Nora et al., 2007). The population
dynamics of the Env region might be important when bNAbs
and novel entry inhibitors become available in the near future.
However, it is hard to observe effects of an anti-retroviral drug-
induced bottleneck on the Env region in vivo.
Thus, we induced variants against anti-retroviral drugs using
primary swarm isolates (Harada et al., 2013). As a result, the
phylogenetic clustering of raltegravir (an integrase inhibitor)-,
lamivudine (a reverse transcriptase inhibitor)- and saquinavir
(a protease inhibitor)-induced variants was entirely distinct from
that of non-drug-treated controls. Among these drug-induced
variants, the variable regions of gp120 were very similar to
each other. Conversely, the non-drug-treated variant was quite
Frontiers in Microbiology | www.frontiersin.org 4 March 2017 | Volume 8 | Article 390
fmicb-08-00390 March 14, 2017 Time: 15:36 # 5
Harada and Yoshimura Driving HIV-1 into a Vulnerable Corner
different from the drug-induced variants. These results imply
that, under selective pressure of non-entry inhibitors, the virus
may choose a representative Env sequence from the viral
population to gain a growth advantage (Harada et al., 2013). In
addition to our results, a supporting study by Mesplede et al.
(2015) showed that treatment with dolutegravir (an integrase
inhibitor) results in a reduction in viral genetic diversity. Further
studies are needed to confirm our observations, but these results
may provide a new paradigm for viral evolution in the novel NAb
plus anti-retroviral drug combination therapy era.
CD4mc CAN EXPOSE HIV-1
NEUTRALIZATION EPITOPES
Binding of CD4 to gp120, is the first essential step of the entry
process. The multiple contacts made by Phe 43 and Arg 59 of
CD4 with gp120 residues in CD4bs contribute significantly to
CD4–gp120 binding (Kwong et al., 1998). The critical Phe 43
of CD4 becomes buried in a binding pocket of gp120, termed
the Phe 43 cavity. This cavity is known to be highly conserved
among the different subtypes and is therefore considered a
particularly interesting target for inhibitors of CD4–gp120
interaction (Kwong et al., 1998).
Molecules that mimic the CD4 receptor, such as soluble CD4
(sCD4), CD4 immunoadhesin (CD4-Ig), sCD4 mini-proteins,
and CD4mc have been developed (Vita et al., 1999; Grupping
et al., 2012). sCD4, CD4-Ig, and sCD4 mini-protein have been
studied as potential therapeutics (Smith et al., 1987; Fisher et al.,
1988; Hussey et al., 1988; Jacobson et al., 2000; Fletcher et al.,
2007; Dereuddre-Bosquet et al., 2012; Gardner et al., 2015).
These studies in patients and non-human primate models have
provided proof of principle that viral entry can be successfully
blocked in vivo. In particular, Gardner et al. (2015) demonstrated
that eCD4-Ig, a fusion of CD4-Ig with a small CCR5-mimetic
peptide, was on average more potent, and much broader than
bNAbs. Moreover, adeno-associated virus-delivered eCD4-Ig,
provided durable protection for immunized monkeys against
high-dose intravenous SHIV challenge (Gardner et al., 2015).
The prototype of CD4mc, NBD-556, was identified in a screen
for inhibitors of the CD4–gp120 interaction (Zhao et al., 2005).
We and others have been exploring the potential of NBD-556-
derived CD4mc as a novel class of HIV entry inhibitor (Madani
et al., 2004, 2008, 2014, 2016, 2017; Narumi et al., 2010, 2011,
2013; Yamada et al., 2010; Yoshimura et al., 2010; Lalonde et al.,
2011, 2012, 2013; Courter et al., 2014; Richard et al., 2015;
Melillo et al., 2016; Mizuguchi et al., 2016; Ohashi et al., 2016).
The binding of CD4mc in the Phe 43 cavity blocks CD4-gp120
interaction and, induces conformational changes in gp120 similar
to those observed upon sCD4 binding (Figure 2B) (Schon et al.,
2006; Haim et al., 2009; Curreli et al., 2014; Kwon et al., 2014).
sCD4 significantly enhance neutralization by CD4i (Thali et al.,
1993) and some V3 NAbs (Lusso et al., 2005). Remarkably, CD4i
and V3 NAbs are present in HIV-infected individuals during
the early stage of infection (Decker et al., 2005). Consequently,
we hypothesized that CD4mc can cause exposure of cryptic
epitopes to antibodies, allowing virus neutralization. As a result,
combinations of CD4mc (NBD-556 or YYA-021) with CD4i
or V3 NAbs produced strong synergistic antiviral interactions
(Yamada et al., 2010; Yoshimura et al., 2010) (Figures 1, 2B).
Moreover, we found that CD4mc sensitized a clinical isolate
to autologous plasma antibodies from the same time point
(Yoshimura et al., 2010).
Recently, this approach has been extended to combining
vaccine with CD4mc. In studies using prototypic CD4mc
BNM compounds, Madani et al. (2014, 2016) demonstrated
that CD4mc sensitized the virus to antibodies elicited by
immunization of humans and monkeys. These studies establish
the proof of concept that CD4mc can sensitize primary viruses to
antibodies that are present in plasma of infected or vaccinated
individuals. In addition, Richard et al. (2015) reported that
CD4mc could efficiently sensitize primary CD4 T cells from
HIV-1-infected individuals to antibody-dependent cell-mediated
cytotoxicity (ADCC) mediated by autologous sera and effector
cells.
Based on these results, further studies are needed to investigate
the effectiveness of delivery methods of CD4mc. Small molecules
such as CD4mc have many advantages over conventional
immunotherapeutic agents, including ease of production and
the potential for oral administration. Furthermore, the use of
bifunctional entry inhibitors that display direct blockade of viral
entry and exposure of epitopes to NAbs should be effective in
passive NAb immunization.
CONCLUSION
Extensive genetic diversity in the Env region presents significant
obstructions to the development of promising therapies and
vaccines against HIV-1. However, selection pressures on the Env
region by NAbs, entry inhibitors, and/or non-entry antiviral
inhibitors, might turn the tide in the fight against HIV-1.
Moreover, bifunctional entry inhibitors such as CD4mc might
potentiate these selection pressures. Thus, by taking advantage
of the adaptation and evolution of HIV resulting from drug and
immune pressure, we might drive HIV-1 into a vulnerable corner.
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